Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Jun 25, 2021

Genentech Announces FDA Emergency Use Authorization for Chugai’s Actemra for Hospitalized Patients with COVID-19

TOKYO, June 25, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Genentech issued a press release on June 24 (local time) regarding the Emergency Use Authorization by the US FDA for Actemra®, a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai, for the treatment of COVID-19 in hospitalized adults and children.

Please refer to the link below for details of the press release:

Trademarks used or mentioned in this release are protected by laws.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top